{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:09:56Z","timestamp":1789193396708,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hematuria is common in autosomal dominant polycystic kidney disease (ADPKD), but whether baseline hematuria predicts long-term kidney outcomes is unknown. We tested its association with kidney function decline, renal survival, and volume growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a single-center ADPKD cohort, 175 patients had standardized urinary sediment assessment in a baseline period (2006\u201311); 173 (99%) were linked to a registry (follow-up up to 20 years). Microscopic hematuria was &amp;gt;5 erythrocytes per high-power field; macroscopic was from clinical history. Outcomes were the estimated glomerular filtration rate (eGFR) slope, a composite of end-stage kidney disease or eGFR halving, and total kidney volume (TKV) growth, adjusted for baseline eGFR, age, and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline hematuria was present in 45 patients (26%; microscopic 15%, macroscopic 17%) and was associated with faster adjusted eGFR decline [mixed-model differential slope: any \u22121.46\u00a0ml\/min\/1.73 m\u00b2\/year (95% confidence interval {CI}, \u22122.12 to \u22120.80); macroscopic \u22121.73 (\u22122.53 to \u22120.93); microscopic \u22121.53 (\u22122.34 to \u22120.73); P\u00a0&amp;lt;\u00a0.001 for all]. The composite end point was more frequent with hematuria (15-year event-free survival 33% vs. 58%; P\u00a0=\u00a0.002); macroscopic hematuria was independently associated [adjusted hazard ratio 1.97 (1.08\u20133.58); P\u00a0=\u00a0.03]. Hematuria was not associated with TKV growth (all P\u00a0&amp;gt;\u00a0.3). Associations persisted after adjustment for baseline kidney volume and albuminuria and in never-treated patients, were dose-dependent for macroscopic hematuria, and strengthened for microscopic hematuria when infection-associated episodes were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline hematuria\u2014particularly macroscopic and non\u2013infection-associated microscopic\u2014independently predicts accelerated functional decline and worse renal survival. Because this prognostic signal is functional rather than volume-driven, this simple, routinely available finding may complement imaging-based risk markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag300","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:32:07Z","timestamp":1788219127000},"source":"Crossref","is-referenced-by-count":0,"title":["Baseline hematuria in autosomal dominant polycystic kidney disease"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-5605","authenticated-orcid":false,"given":"Andreas","family":"Serra","sequence":"first","affiliation":[{"name":"Suisse ADPKD , Klinik Hirslanden, Z\u00fcrich ,","place":["Switzerland"]},{"name":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana Henschkowski","family":"Serra","sequence":"additional","affiliation":[{"name":"Suisse ADPKD , Klinik Hirslanden, Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Severin","sequence":"additional","affiliation":[{"name":"Suisse ADPKD , Klinik Hirslanden, Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Russmann","sequence":"additional","affiliation":[{"name":"Suisse ADPKD , Klinik Hirslanden, Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026091201520023200_bib1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le\u00a0Gall","year":"2019","journal-title":"Lancet"},{"key":"2026091201520023200_bib2","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le\u00a0Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026091201520023200_bib3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"2026091201520023200_bib4","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2026091201520023200_bib5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091201520023200_bib6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091201520023200_bib7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026091201520023200_bib8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091201520023200_bib9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le\u00a0Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2026091201520023200_bib10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group","year":"2025","journal-title":"Kidney Int"},{"key":"2026091201520023200_bib11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/bmj.323.7309.386","article-title":"Causes of haematuria in adult polycystic kidney disease","volume":"323","author":"Dedi","year":"2001","journal-title":"BMJ"},{"key":"2026091201520023200_bib12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0272-6386(12)80541-5","article-title":"Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease","volume":"20","author":"Gabow","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"2026091201520023200_bib13","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1681\/ASN.V8101560","article-title":"Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease","volume":"8","author":"Johnson","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"2026091201520023200_bib14","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMcp012694","article-title":"Microscopic hematuria","volume":"348","author":"Cohen","year":"2003","journal-title":"N Engl J Med"},{"key":"2026091201520023200_bib15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"2026091201520023200_bib16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026091201520023200_bib17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00365513.2000.12056993","article-title":"European urinalysis guidelines","volume":"60","author":"Kouri","year":"2000","journal-title":"Scand J Clin Lab Invest"},{"key":"2026091201520023200_bib18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/ki.1982.16","article-title":"Haematuria: a simple method for identifying glomerular bleeding","volume":"21","author":"Fairley","year":"1982","journal-title":"Kidney Int"},{"key":"2026091201520023200_bib19","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091201520023200_bib20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2008.558","article-title":"Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months","volume":"75","author":"Kistler","year":"2009","journal-title":"Kidney Int"},{"key":"2026091201520023200_bib21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v035.i09","article-title":"JM: an R package for the joint modelling of longitudinal and time-to-event data","volume":"35","author":"Rizopoulos","year":"2010","journal-title":"J Stat Soft"},{"key":"2026091201520023200_bib22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"key":"2026091201520023200_bib23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2215\/CJN.03100608","article-title":"Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients","volume":"4","author":"Nishiura","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091201520023200_bib24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/jama.2011.1141","article-title":"Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease","volume":"306","author":"Vivante","year":"2011","journal-title":"JAMA"},{"key":"2026091201520023200_bib25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1681\/ASN.V561349","article-title":"Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease","volume":"5","author":"Chapman","year":"1994","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag300\/70885261\/sfag300.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag300\/70885261\/sfag300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag300\/70885261\/sfag300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:52:06Z","timestamp":1789192326000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag300\/8777094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag300","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,31]]},"article-number":"sfag300"}}